Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MET642 after single and multiple ascending oral dose administration in healthy subjects

Next Previous
Trial Profile

A randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MET642 after single and multiple ascending oral dose administration in healthy subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MET 642 (Primary)
  • Indications Inflammatory bowel diseases; Non-alcoholic steatohepatitis
  • Focus Adverse reactions; First in man
  • Sponsors Metacrine

Most Recent Events

  • 26 Jun 2021 Results presented at The International Liver Congress 2021
  • 17 Jun 2021 According to the Metacrine media release, data from this trial will be present at the European Association for the Study of the Liver (EASL) International Liver Congress 2021, being held virtually from June 23-26, 2021.
  • 11 Mar 2021 Final results of this trial will be presented as a distinguished abstract at the 2021 NASH-TAG Conference according to the Metacrine Meia release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top